CB: Tissue Resources and Molecular Pathology

CB：组织资源和分子病理学

• 批准号: 8731338
• 负责人: IGNACIO I. WISTUBA
• 金额: $ 4.92万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-12 至 2014-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8731338
• 关键词: 3-Dimensional; Aliquot; Arts; Biological Markers; Blood specimen; Cancer Center; Cancer cell line; Cataloging; Catalogs; Cell Line; Cells; Clinical; Clinical Data; Collaborations; DNA; Data; Databases; Epithelial Cells; Funding; Human; Image; Image Analysis; Immunohistochemistry; In Situ; Institution; Lung; Malignant - descriptor; Malignant neoplasm of lung; Medical center; Methodology; Molecular; Non-Malignant; Paraffin; Pathologic; Pathologist; Pathology; Patients; Peer Review; Process; RNA; Research; Research Personnel; Resources; Site; Source; Specimen; Techniques; Texas; Tissue Microarray; Tissues; Translational Research; Tumor Cell Line; United States National Institutes of Health; Universities; Xenograft procedure; anticancer research; base; c new; design; experience; innovation; molecular pathology; programs; tissue resource; tumor

SPORE Core B. Pathology and Tissue Resources Core. The Tissue Resources and Molecular Pathology Core will provide routine and innovative tissues and materials, as well as conventional and molecular pathology assistance, essential for achieving the aims of the SPORE projects. Routine materials include tumors and non-malignant lung specimens and tumor cell lines. Over 2,500 well-characterized tumors with annotated clinical data and 200 cell lines have been banked, and over 15,000 aliquots of tumor or cell line pellets, RNA or DNA or paraffin sections are available to SPORE investigators. State-of-art molecular pathology facilities devoted to lung cancer translational research directed by experienced lung cancer molecular pathologists are available. Our Aim 1 is to collect, process, store, catalog and distribute tissues, cells and blood specimens, both malignant and non-malignant, and relevant clinico-pathologic data, as requested by the various component projects of the SPORE program. Aim 2 is to develop and utilize innovative or routine tissue and cell resources that will aid in the successful completion of the SPORE program aims. Innovative materials include: a) cell pellets and tissue microarrays (TMAs) and high throughput image analysis of in situ techniques, b) new lung cancer cell lines and lung cancer xenografts made directly from patient specimens, c) new immortalized and non-immortalized human bronchial epithelial cells (HBECs) and 3-dimensional organotypic cultures. Aim 3 is to perform and interpret tissue-based molecular methodologies in close collaboration with the component projects of the SPORE program to satisfy their approved aims. This includes immunohistochemistry (IHC) information on over 90 lung cancer relevant biomarkers on the TMAs with information stored in an image database and integrated with the clinical annotations. Aim 4 is to promote collaboration among investigators in this SPORE, other lung cancer SPORES, other investigators in MD Anderson Cancer Center, UT Southwestern Medical Center, and other investigators nationally and internationally pursuing lung cancer relevant research. All of our five projects in this application will utilize CORE materials. Heavy utilization of our routine and innovative materials, and close interactions with the SPORE investigators will greatly aid the successful completion of the aims of our SPORE proposal. The SPORE Tissue Resource Core is designed and has operated as a facility receiving support from several other sources beyond SPORE funding including in a manner non-overlapping with other Cancer Center activities at both MD Anderson and UT Southwestern Medical Centers. This means that SPORE discoveries and data have far reaching beneficial effects across the range of lung cancer research conducted at these two institutions.

孢子核心B。病理学和组织资源核心。组织资源与分子生物学 病理核心将提供常规和创新的组织和材料，以及传统和 分子病理学援助，这对实现SPORE项目的目标至关重要。常规材料 包括肿瘤和非恶性肺样本和肿瘤细胞系。超过2，500个特征良好的 已经将具有注释的临床数据的肿瘤和200个细胞系储存起来， 或细胞系沉淀、RNA或DNA或石蜡切片可供SPORE研究者使用。最新技术 分子病理学设施致力于肺癌转化研究，由经验丰富的肺 有癌症分子病理学家。我们的目标1是收集、处理、储存、编目和分发 组织、细胞和血液标本，包括恶性和非恶性标本，以及相关临床病理学数据， 按照SPORE计划的各个组成项目的要求。目标二是开发利用 有助于成功完成孢子培养的创新或常规组织和细胞资源 方案目标。创新材料包括：a）细胞团和组织微阵列（TMA）以及高通量 原位技术图像分析，B）制备的新肺癌细胞系和肺癌异种移植物 c）新的永生化和非永生化人支气管上皮细胞 （HBEC）和三维器官型培养物。目的3是执行和解释基于组织的分子 与SPORE计划的组成项目密切合作，以满足其 批准的目标。这包括超过90种肺癌相关的免疫组织化学（IHC）信息 将TMA上的生物标志物与存储在图像数据库中的信息结合起来， 注释。目的4是促进研究者在这个SPORE（其他肺癌）领域的合作。 SPORES，MD安德森癌症中心，UT西南医学中心和其他 研究人员在国内和国际上进行肺癌相关研究。我们的五个项目 本申请将利用CORE材料。大量使用我们的常规和创新材料， 与SPORE调查人员的密切互动将极大地有助于成功完成我们的目标， SPORE提案。SPORE组织资源中心的设计和运作是作为一个设施， 除SPORE供资外，其他几个来源的支持，包括与 MD安德森和UT西南医学中心的其他癌症中心活动。这意味 SPORE的发现和数据对肺癌的范围有深远的有益影响， 在这两个机构进行的研究。